Head-To-Head Contrast: Krystal Biotech (NASDAQ:KRYS) & Palvella Therapeutics (NASDAQ:PVLA)

Krystal Biotech (NASDAQ:KRYS) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Risk & Volatility

Krystal Biotech has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the S&P 500.

Valuation and Earnings

This table compares Krystal Biotech and Palvella Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13 million	26.28	$204.83 million	$7.98	43.30
Palvella Therapeutics	$42.81 million	50.62	-$41.72 million	($4.83)	-31.14

Krystal Biotech has higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Krystal Biotech and Palvella Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0	2	10	1	2.92
Palvella Therapeutics	1	0	12	2	3.00

Krystal Biotech currently has a consensus target price of $365.40, indicating a potential upside of 5.74%. Palvella Therapeutics has a consensus target price of $209.14, indicating a potential upside of 39.07%. Given Palvella Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Palvella Therapeutics is more favorable than Krystal Biotech.

Institutional and Insider Ownership

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Krystal Biotech and Palvella Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	54.82%	19.34%	17.65%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Summary

Krystal Biotech beats Palvella Therapeutics on 9 of the 15 factors compared between the two stocks.

About Krystal Biotech

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

About Palvella Therapeutics

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.